In our study, we have selected a lipid composition that closely resembles that of the first approved and marketed LNP-siRNA drug for targeting hepatocytes in the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis, a fatal rare disease [63]. Here, TTR is linked to polyneuropathy.